Lewis Kevin M, Li Qing, Jones Drew S, Corrales JoMichelle D, Du Hongyan, Spiess Philippe E, Lo Menzo Emanuele, DeAnda Abe
Baxter Healthcare Corporation, Deerfield, IL.
Baxter Healthcare Corporation, Deerfield, IL.
Surgery. 2017 Mar;161(3):771-781. doi: 10.1016/j.surg.2016.09.022. Epub 2016 Nov 10.
Clinical studies investigating topical hemostatic agents have not used standardized definitions for intraoperative bleeding. The Food and Drug Administration has recently sought use of a validated, clinician-reported scale to standardized bleeding sites in these clinical studies. The intent of a scale is to reduce patient risk, generate labeling claims, and allow comparisons among study results. We describe the development and validation of an intraoperative bleeding severity scale.
A concept phase defined the framework of the scale. A feasibility and validation phase investigated the usability, clarity, relevance, and reliability (ie, intra- and interobserver concordance) among surgeons and surgical specialties as required by the Food and Drug Administration for the validation of a clinician-reported scale. Data were collected using an online tool. A total of 144 surgeons participated in the 3 phases.
The scale developed during the concept phase achieved an average intraobserver concordance of 0.97 and an interobserver concordance of 0.89 in the feasibility phase (N = 33); a concordance of 1.0 is perfect. The scale was refined and then achieved an average intraobserver concordance of 0.98 and an interobserver concordance of 0.91 in the validation phase with unanimous agreement by surgeons from multiple surgical specialties that the scale can be implemented into clinical studies (N = 102).
This study validated an intraoperative bleeding severity scale for use in clinical studies investigating hemostatic agents. The scale was usable, clear, and clinically relevant with excellent reliability. The scale fulfills requirements of the Food and Drug Administration for a clinician-reported scale and can be used to generate clinically meaningful labeling claims.
调查局部止血剂的临床研究尚未对术中出血采用标准化定义。美国食品药品监督管理局最近寻求使用一种经过验证的、由临床医生报告的量表,以在这些临床研究中对出血部位进行标准化。量表的目的是降低患者风险、生成标签声明,并允许对研究结果进行比较。我们描述了一种术中出血严重程度量表的开发和验证过程。
概念阶段定义了量表的框架。可行性和验证阶段按照美国食品药品监督管理局对临床医生报告量表验证的要求,调查了外科医生和外科专业之间的可用性、清晰度、相关性和可靠性(即观察者内和观察者间的一致性)。数据通过在线工具收集。共有144名外科医生参与了这三个阶段。
在概念阶段开发的量表在可行性阶段(N = 33)观察者内一致性平均为0.97,观察者间一致性为0.89;一致性为1.0表示完全一致。该量表经过完善,然后在验证阶段观察者内一致性平均为0.98,观察者间一致性为0.91,多个外科专业的外科医生一致认为该量表可用于临床研究(N = 102)。
本研究验证了一种用于调查止血剂的临床研究的术中出血严重程度量表。该量表可用、清晰且具有临床相关性,可靠性极佳。该量表满足美国食品药品监督管理局对临床医生报告量表的要求,可用于生成具有临床意义的标签声明。